【摘要】 肿瘤突变负荷（TMB）被认为是预测免疫治疗应答和效果方面极具潜力的肿瘤标志物（TM）。然而，特定基因的突变与TMB之间的关系仍不清楚。其是否可以作为免疫检查点抑制剂（ICIs）疗效的预测性TM也是未知的。TMB-H通常意味着肿瘤细胞可能拥有更多的新抗原，这些新抗原可以被免疫系统识别，从而在某些患者中引发免疫反应。本文将对胃癌患者TMB与关键基因突变相关性的研究进展作一综述，为未来胃癌的治疗研究提供方向。更多还原

【Abstract】 Tumor mutation burden(TMB) is considered to be a promising tumor marker(TM) for predicting the response and efficacy of immunotherapy.However, the relationship between gene-specific mutations and TMB remains unclear. Whether it can be used as a predictive TM for the efficacy of immune checkpoint inhibitors(ICIs) is also unknown. TMB-H usually means that tumor cells may have more new antigens that can be recognized by the immune system, triggering an immune response in some patients. This article will review the research progress of the correlation between TMB and key gene mutations in patients with gastric cancer, and provide directions for future research on the treatment of gastric cancer.更多还原